Improving the efficacy of peptide vaccines in cancer immunotherapy

Int Immunopharmacol. 2023 Aug 3;123:110721. doi: 10.1016/j.intimp.2023.110721. Online ahead of print.ABSTRACTPeptide vaccines have shown great potential in cancer immunotherapy by targeting tumor antigens and activating the patient's immune system to mount a specific response against cancer cells. However, the efficacy of peptide vaccines in inducing a sustained immune response and achieving clinical benefit remains a major challenge. In this review, we discuss the current status of peptide vaccines in cancer immunotherapy and strategies to improve their efficacy. We summarize the recent advancements in the development of peptide vaccines in pre-clinical and clinical settings, including the use of novel adjuvants, neoantigens, nano-delivery systems, and combination therapies. We also highlight the importance of personalized cancer vaccines, which consider the unique genetic and immunological profiles of individual patients. We also discuss the strategies to enhance the immunogenicity of peptide vaccines such as multivalent peptides, conjugated peptides, fusion proteins, and self-assembled peptides. Although, peptide vaccines alone are weak immunogens, combining peptide vaccines with other immunotherapeutic approaches and developing novel approaches such as personalized vaccines can be promising methods to significantly enhance their efficacy and improve the clinical outcomes for cancer patients.PMID:37543011 | DOI:10.1016/j.intimp.2023.110721

Source: International Immunopharmacology - August 5, 2023 Category: Allergy & Immunology Authors: Fatemeh Zahedipour Khadijeh Jamialahmadi Parvin Zamani Mahmoud Reza Jaafari Source Type: research